<i>In vivo</i> dosimetry for gynaecological brachytherapy using a novel position sensitive radiation detector: Feasibility study

Reniers, Brigitte; Landry, Guillaume; Eichner, R.; Hallil, A; Verhaegen, Frank

doi:10.1118/1.3693049

Cited by 26 publications

(29 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Occasional IVD feasibility studies have also been conducted in some clinics. [12][13][14][15][16][17][18][19][20][21][22][23][24] However, routine implementations of IVD for error detection monitoring and QA of the BT treatments is yet to come. One reason for this may be that the cost vs benefit relation of IVD is not established and that robust IVD systems that do not leave a significant footprint on the treatment workflow are not commercially available.…”

Section: Treatment Errors In Btmentioning

confidence: 99%

“…The focus of this article is on real-time dosimetry, given the capacity for online monitoring of BT treatments and the superior error detection efficiency compared with passive dosimetry. 14,17,22,25 UNCERTAINTIES, ERRORS AND THE NEED FOR IN VIVO DOSIMETRY Uncertainties during brachytherapy Uncertainty analyses occupy a substantial portion of the literature and cover various aspects of BT treatment workflow. Uncertainties related to treatment planning arise partly from source calibration uncertainties 26 and imperfections of the dose calculation protocols.…”

Section: Treatment Errors In Btmentioning

confidence: 99%

“…Similar concepts have been implemented during phantom measurements. 14,18,22,25,85 Nakano et al 86 adapted statistically based discrepancy criteria during phantom experiments using HDR BT sources, where the discrepancy was based on measured and expected source coordinates rather than on dose rates.…”

Section: Statistical Discrepancy Criterionmentioning

confidence: 99%

“…73 If an energy correction coefficient was applied, the results agreed within 5%, which corresponded to experimental uncertainties. Reniers et al 22 measured the variation of the MOSFET response with distance and used a linear fit through the measurements as an energy correction factor.…”

mentioning

confidence: 99%

See 3 more Smart Citations

In vivodosimetry: trends and prospects for brachytherapy

Kertzscher¹,

Rosenfeld²,

Beddar³

et al. 2014

BJR

View full text Add to dashboard Cite

The error types during brachytherapy (BT) treatments and their occurrence rates are not well known. The limited knowledge is partly attributed to the lack of independent verification systems of the treatment progression in the clinical workflow routine. Within the field of in vivo dosimetry (IVD), it is established that real-time IVD can provide efficient error detection and treatment verification. However, it is also recognized that widespread implementations are hampered by the lack of available high-accuracy IVD systems that are straightforward for the clinical staff to use. This article highlights the capabilities of the state-of-the-art IVD technology in the context of error detection and quality assurance (QA) and discusses related prospects of the latest developments within the field. The article emphasizes the main challenges responsible for the limited practice of IVD and provides descriptions on how they can be overcome. Finally, the article suggests a framework for collaborations between BT clinics that implemented IVD on a routine basis and postulates that such collaborations could improve BT QA measures and the knowledge about BT error types and their occurrence rates.

show abstract

Section: Treatment Errors In Btmentioning

confidence: 99%

Section: Treatment Errors In Btmentioning

confidence: 99%

Section: Statistical Discrepancy Criterionmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

In vivodosimetry: trends and prospects for brachytherapy

Kertzscher¹,

Rosenfeld²,

Beddar³

et al. 2014

BJR

View full text Add to dashboard Cite

show abstract

“…[1][2][3][4][5][6][7][8][9][10][11][12][13][14][15] Since the treatment dose is delivered in a few fractions by a moving radioactive source and high dose gradients are involved, high-dose-rate (HDR) brachytherapy is among the main applications for real-time in vivo dosimetry systems. Many groups have investigated the development of real-time detectors that can be inserted in catheters or anatomical orifices, and various types of detectors have been used (MOSFETs, RL/OSLDs, diodes, plastic scintillators).…”

Section: Introductionmentioning

confidence: 99%

On the use of a single‐fiber multipoint plastic scintillation detector for ¹⁹²Ir high‐dose‐rate brachytherapy

2013

View full text Add to dashboard Cite

Purpose: The goal of this study was to prove the feasibility of using a single-fiber multipoint plastic scintillation detector (mPSD) as an in vivo verification tool during 192 Ir high-dose-rate brachytherapy treatments. Methods: A three-point detector was built and inserted inside a catheter-positioning template placed in a water phantom. A hyperspectral approach was implemented to discriminate the different optical signals composing the light output at the exit of the single collection optical fiber. The mPSD was tested with different source-to-detector positions, ranging from 1 to 5 cm radially and over 10.5 cm along the longitudinal axis of the detector, and with various integration times. Several strategies for improving the accuracy of the detector were investigated. The device's accuracy in detecting source position was also tested. Results: Good agreement with the expected doses was obtained for all of the scintillating elements, with average relative differences from the expected values of 3.4 ± 2.1%, 3.0 ± 0.7%, and 4.5 ± 1.0% for scintillating elements from the distal to the proximal. A dose threshold of 3 cGy improved the general accuracy of the detector. An integration time of 3 s offered a good trade-off between precision and temporal resolution. Finally, the mPSD measured the radioactive source positioning uncertainty to be no more than 0.32 ± 0.06 mm. The accuracy and precision of the detector were improved by a dose-weighted function combining the three measurement points and known details about the geometry of the detector construction. Conclusions: The use of a mPSD for high-dose-rate brachytherapy dosimetry is feasible. This detector shows great promise for development of in vivo applications for real-time verification of treatment delivery.

show abstract

3D in vivo dosimetry of HDR gynecological brachytherapy using micro silica bead TLDs

Jaberi

Babaloui

Siavashpour

et al. 2022

J Applied Clin Med Phys

View full text Add to dashboard Cite

This study aimed to evaluate the feasibility of defining an in vivo dosimetry (IVD) protocol as a patient-specific quality assurance (PSQA) using the bead thermoluminescent dosimeters (TLDs) for point and 3D IVD during brachytherapy (BT) of gynecological (GYN) cancer using 60 Co high-dose-rate (HDR) source. Methods: The 3D in vivo absorbed dose verification within the rectum and bladder as organs-at-risk was performed by bead TLDs for 30 GYN cancer patients. For rectal wall dosimetry, 80 TLDs were placed in axial arrangements around a rectal tube covered with a layer of gel. Ten beads were placed inside the Foley catheter to get the bladder-absorbed dose. Beads TLDs were localized and defined as control points in the treatment planning system (TPS) using CT images of the patients. Patients were planned and treated using the routine BT protocol. The experimentally obtained absorbed dose map of the rectal wall and the point dose of the bladder were compared to the TPSs predicted absorbed dose at these control points. Results: Relative difference between TPS and TLDs results were −8.3% ± 19.5% and −7.2% ± 14.6% (1SD) for rectum-and bladder-absorbed dose, respectively.Gamma analysis was used to compare the calculated with the measured absorbed dose maps. Mean gamma passing rates of 84.1%, 90.8%, and 92.5% using the criteria of 3%/2 mm, 3%/3 mm, and 4%/2 mm were obtained, respectively. Eventually, a "considering level" of at least 85% as pass rate with 4%/2-mm criteria was recommended. Conclusions: A 3D IVD protocol employing bead TLDs was presented to measure absorbed doses delivered to the rectum and bladder during GYN HDR-BT as a reliable PSQA method. 3D rectal absorbed dose measurements were performed. Differences between experimentally measured and planned absorbed dose maps were presented in the form of a gamma index, which may be used as a warning for corrective action.

show abstract

In vivo dosimetry for gynaecological brachytherapy using a novel position sensitive radiation detector: Feasibility study

Cited by 26 publications

References 30 publications

In vivodosimetry: trends and prospects for brachytherapy

In vivodosimetry: trends and prospects for brachytherapy

On the use of a single‐fiber multipoint plastic scintillation detector for ¹⁹²Ir high‐dose‐rate brachytherapy

3D in vivo dosimetry of HDR gynecological brachytherapy using micro silica bead TLDs

Contact Info

Product

Resources

About

In vivo dosimetry for gynaecological brachytherapy using a novel position sensitive radiation detector: Feasibility study

Cited by 26 publications

References 30 publications

In vivodosimetry: trends and prospects for brachytherapy

In vivodosimetry: trends and prospects for brachytherapy

On the use of a single‐fiber multipoint plastic scintillation detector for 192Ir high‐dose‐rate brachytherapy

3D in vivo dosimetry of HDR gynecological brachytherapy using micro silica bead TLDs

Contact Info

Product

Resources

About

On the use of a single‐fiber multipoint plastic scintillation detector for ¹⁹²Ir high‐dose‐rate brachytherapy